Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.
Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest in hematological malignancies. This particular information has encouraged the therapeutic use of anti-angiogenic drugs in MMM. In the current review, we summarize the general concepts regarding angiogenesis, assessment of angiogenesis in hematological malignancies and then the current literature on angiogenesis and anti-angiogenic therapy in MMM.
Arora
Brijesh
B
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Mesa
Ruben
R
Tefferi
Ayalew
A
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D055728:Primary Myelofibrosis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D013792:Thalidomide / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D016207:Cytokines; D013792:Thalidomide